Statement re ECO Animal Health and The Pirbright Institute sign second poultry vaccine development licencing deal.
11 September 2019
ECO Animal Health Group plc
ECO Animal Health and The Pirbright Institute sign second poultry vaccine development licencing deal
ECO Animal Health Ltd (ECO), a wholly owned subsidiary of ECO Animal Health Group plc, is pleased to announce that it has entered into a second worldwide exclusive research partnership with The Pirbright Institute, United Kingdom, to develop another novel vaccine for use in chickens.
Innovative technologies developed at Pirbright will use a Marek’s disease virus vector to express multiple protective components against the economically important poultry viral diseases of infectious bursal disease virus (IBDV), Newcastle disease virus (NDV) and infectious laryngotracheitis virus (ILTV) which cause significant systemic and respiratory damage.
The global poultry biologicals market is worth c. $2.3 billion and forecast to grow with a CAGR of 5-6%. The Marek’s disease, IBDV, NDV and ILTV segments are collectively worth c. $470 million.
Professor Venugopal Nair, Head of Avian Viral Diseases at the Pirbright Institute, states: “The novel vaccine will have the potential to induce simultaneous protection against Marek’s disease as well as the other major diseases caused by IBDV, NDV and ILTV that threaten poultry health and production worldwide.”
Commenting Marc Loomes, CEO of ECO Animal Health Group plc, said: “We are delighted to have partnered with the Pirbright Institute again to develop another novel vaccine for use in chickens. The use of the Marek’s disease vector in this technology is a significant advancement over other recombinant vaccines and will help widen the potential use of this vaccine in broilers and in breeding stock.”
ECO Animal Health Group plc
Marc Loomes, CEO
020 8447 8899
N+1 Singer (Nominated Advisor and Joint Broker)
020 7496 3000
Peel Hunt (Joint Broker)
020 7418 8900
Dr Christopher Golden
020 3934 6637
The Pirbright Institute
About ECO Animal Health Ltd
ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.
About The Pirbright Institute
The Pirbright Institute is a world leading centre of excellence in research and surveillance of virus diseases of farm animals and viruses that spread from animals to humans. It receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), and works to enhance capability to contain, control and eliminate these economically and medically important diseases through highly innovative fundamental and applied bioscience.
Copyright Business Wire 2019